Products

AGGRASTAT, in combination with heparin, is indicated for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischaemic events.

Treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Palliative treatment of multiple myeloma and advanced ovarian adenocarcinoma.

Treatment of the following dermatoses: atopic dermatitis, eczematous dermatitis, nummular eczema, contact dermatitis, anal and vulval pruritus, otitis externa, seborrhoeic dermatitis, eczematised psoriasis, neurodermatitis.

Adrenaline 1:10,000. An adjunct in the management of cardiac arrest. Adrenaline 1:1,000. The drug of choice in the emergency treatment of acute severe anaphylactic reactions due to insect bites, drugs and other allergens. It may also be used for the symptomatic relief of respiratory distress due to bronchospasm.

Hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. For the treatment of serious or life threatening infections due to sensitive organisms involving the following organ systems:

• - Lower respiratory tract infections (gram-negative organisms)
• - Skin and skin structure
• - Septicaemia
• - Bone and joint - Urinary tract

Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication.

Indicated where it is necessary to dilate the pupil and paralyse accommodation.

Effective relief and prevention of allergic rhinitis including hayfever.

General relief from the symptoms of coughs and sore throats associated with colds

Treatment of acute, nonmalignant gastric and duodenal ulcers. Maintenance therapy to prevent the recurrence of duodenal ulcers.

For prevention of blood clotting and reduces the risk of heart attack and stroke in patients with known cardiovascular or cerebrovascular disease.

For the treatment of bacterial conjunctivitis. For use under medical supervision only in the treatment of other superficial ocular infections caused by chloramphenicol-sensitive organisms.

For the treatment and specific prevention of hypokalaemia.

Monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Relief of pain in acute gout. Colchicine should not be used unless NSAIDS are contraindicated, or have been used and found to lack analgesic efficacy or to have unacceptable side effects in the individual patient. Colchicine is not an analgesic and does not provide relief from other types of pain.

COUMADIN is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. COUMADIN is indicated for the prophylaxis andor treatment of the thromboembolic complications associated with atrial fibrillation. COUMADIN is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (TIA, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. COUMADIN is indicated for use as an adjunct in the treatment of coronary occlusion.